The success of ADCs in NSCLC was demonstrated in the DESTINY-Lung 01 trial evaluating trastuzumab deruxtecan (TDX-d) in patients with metastatic, HER2-mutant NSCLC [8]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.